Adaptive Biotechnologies (ADPT) Liabilities and Shareholders Equity (2018 - 2026)

Adaptive Biotechnologies has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $505.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $505.9 million, down 0.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 8.56% YoY), and the FY2025 annual result was $512.7 million, down 4.94% from the prior year.
• Liabilities and Shareholders Equity came in at $505.9 million for Q1 2026 at Adaptive Biotechnologies, down from $512.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $884.2 million in Q3 2022 to a low of $490.6 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $620.3 million (2024), against an average of $656.5 million.
• Across the five-year window, Liabilities and Shareholders Equity dropped 23.5% in 2024 and decreased 0.96% in 2026, its largest moves.
• Adaptive Biotechnologies' Liabilities and Shareholders Equity stood at $856.6 million in 2022, then decreased by 22.82% to $661.1 million in 2023, then slipped by 18.42% to $539.4 million in 2024, then retreated by 4.94% to $512.7 million in 2025, then retreated by 1.32% to $505.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $505.9 million (Q1 2026), $512.7 million (Q4 2025), and $490.6 million (Q3 2025), per Business Quant data.